Suppr超能文献

极光激酶 B 抑制:癌症的一种潜在治疗策略。

Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.

机构信息

The Operation Eyesight Universal Institute for Eye Cancer, L.V. Prasad Eye Institute, Bhubaneswar 751024, India.

School of Biotechnology, KIIT University, Bhubaneswar 751024, India.

出版信息

Molecules. 2021 Apr 1;26(7):1981. doi: 10.3390/molecules26071981.

Abstract

Aurora kinase B (AURKB) is a mitotic serine/threonine protein kinase that belongs to the aurora kinase family along with aurora kinase A (AURKA) and aurora kinase C (AURKC). AURKB is a member of the chromosomal passenger protein complex and plays a role in cell cycle progression. Deregulation of AURKB is observed in several tumors and its overexpression is frequently linked to tumor cell invasion, metastasis and drug resistance. AURKB has emerged as an attractive drug target leading to the development of small molecule inhibitors. This review summarizes recent findings pertaining to the role of AURKB in tumor development, therapy related drug resistance, and its inhibition as a potential therapeutic strategy for cancer. We discuss AURKB inhibitors that are in preclinical and clinical development and combination studies of AURKB inhibition with other therapeutic strategies.

摘要

极光激酶 B(AURKB)是一种有丝分裂丝氨酸/苏氨酸蛋白激酶,属于极光激酶家族,与极光激酶 A(AURKA)和极光激酶 C(AURKC)一起。AURKB 是染色体乘客蛋白复合物的成员,在细胞周期进展中发挥作用。在几种肿瘤中观察到 AURKB 的失调,其过表达常与肿瘤细胞侵袭、转移和耐药性有关。AURKB 已成为一个有吸引力的药物靶点,导致小分子抑制剂的开发。这篇综述总结了最近关于 AURKB 在肿瘤发生、治疗相关耐药性中的作用及其作为癌症潜在治疗策略的抑制作用的发现。我们讨论了处于临床前和临床开发阶段的 AURKB 抑制剂以及 AURKB 抑制与其他治疗策略的联合研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cb9/8037052/c1679fafb190/molecules-26-01981-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验